Results 11 to 20 of about 129 (87)
MedCommCancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that promotes cancer cell proliferation, invasion, and drug resistance. In this study, CIP2A expression was found to be higher in lung cancer tissues compared to adjacent normal ...
In‐ho Jeong +4 more
doaj +2 more sources
Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients
Egyptian Journal of Medical Human Genetics, 2020 Background Protein phosphatase 2A (PP2A) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibits PP2A proteolytic degradation of c-Myc and enhances cell growth and tumor formation in several tissues.
Roxan E. Shafik +5 more
doaj +1 more source
EBioMedicine, 2019 Background: Triple-negative breast cancer (TNBC) remains difficult to be targeted. SET and cancerous inhibitor of protein phosphatase 2A (CIP2A) are intrinsic protein-interacting inhibitors of protein phosphatase 2A (PP2A) and frequently overexpressed in
Chun-Yu Liu +10 more
doaj +1 more source
OCT4 Represses Inflammation and Cell Injury During Orchitis by Regulating CIP2A Expression
Frontiers in Cell and Developmental Biology, 2021 Octamer-binding transcription factor 4 (OCT4) and cancerous inhibitor of protein phosphatase 2A (CIP2A) are upregulated in testicular cancer and cell lines.
Ruifeng Zeng +8 more
doaj +1 more source
Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. [PDF]
PLoS ONE, 2011 BackgroundLung cancer is the leading cause of cancer deaths worldwide, with a five-year overall survival rate of only 15%. Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein inhibiting PP2A in many human malignancies.
Liang Ma +11 more
doaj +1 more source
Assessment of CIP2A and ROCK-I expression and their prognostic value in breast cancer
Polish Journal of Pathology, 2020 Breast cancer is the most leading cause of cancer death in females worldwide. Identification of novel biomarkers for prognosis is required. Imunohistochemical evaluation of CIP2A and ROCK-1 expressions in 126 breast tissue specimens stratified as 21 ...
Nisreen Tawab Osman +2 more
doaj +1 more source
Prognostic value of the NLR combined with CIP2A in the serum of patients with colorectal cancer
BMC Surgery, 2021 Objective This study aimed to investigate the prognostic value of CIP2A (cancerous inhibitor of protein phosphatase 2A) and the NLR (neutrophil–lymphocyte ratio) in the serum of patients with CRC (colorectal cancer) after resection.
Wei Chen +9 more
doaj +1 more source
CIP2A expression is increased in prostate cancer
Journal of Experimental & Clinical Cancer Research, 2010 Background The CIP2A protein is a recently characterized oncoprotein which inhibits protein phosphatase 2A activity. Expression of CIP2A has been detected in several carcinomas, but its expression and significance in prostate cancer has not been examined
Ristimäki Ari +2 more
doaj +1 more source
Cell Communication and Signaling, 2020 Background Increasing evidence has revealed a close correlation between cancerous inhibitor of protein phosphatase 2A (CIP2A) and cancer progression. CIP2A has been shown to participate in diverse biological processes, such as development, tumorigenic ...
Wei Chen +5 more
doaj +1 more source
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]
PLoS ONE, 2013 Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu +6 more
doaj +1 more source